Shane Ward

Companies

• Cidara TherapeuticsChief operating officer Mar 13, 2023 to now¹
• Cidara TherapeuticsGeneral counsel Aug 27, 2021 to now²
• BELLICUM PHARMACEUTICALS, INCGeneral counsel May 29, 2018 to Jun 2, 2020³
• Aravive, Inc.General counsel Jan 31, 2017 to Feb 12, 2018⁴
• Aravive, Inc.SVP, Legal and Compliance Apr 8, 2015 to Oct 13, 2016⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Cidara Therapeutics CDTX0 shares⁶Jan 7, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

• Jan 7, 2026Returned to company 25,083 shares at $221.50 of Cidara Therapeutics⁶
• Dec 10, 2025Sold 9,959 shares at $220.08 of Cidara Therapeutics⁷
• Dec 10, 2025Exercised options 6,459 shares at $20.20 of Cidara Therapeutics⁷
• Dec 10, 2025Exercised options 3,500 shares at $16.65 of Cidara Therapeutics⁷
• Dec 10, 2025Shares withheld for tax 15,041 shares at $219.60 of Cidara Therapeutics⁷
• Mar 31, 2025Granted 25,000 shares of Cidara Therapeutics⁸
• Mar 11, 2025Sold 1,664 shares at $21.96 of Cidara Therapeutics⁹
• Mar 15, 2024Granted 120,000 shares of Cidara Therapeutics¹⁰
• Mar 11, 2024Sold 20,473 shares at $0.67 of Cidara Therapeutics¹¹
• Mar 27, 2023Granted 126,667 shares of Cidara Therapeutics¹²
• Mar 13, 2023Sold 4,329 shares at $1.53 of Cidara Therapeutics¹³
• Mar 31, 2022Shares withheld for tax 23,122 shares at $0.83 of Cidara Therapeutics¹⁴
• Mar 31, 2022Granted 69,027 shares of Cidara Therapeutics¹⁴
• Mar 31, 2022Granted 35,000 shares of Cidara Therapeutics¹⁴